On July 31, 2026 Ratio Therapeutics, Inc. (Ratio), a clinical-stage pharmaceutical company developing best-in-class radiopharmaceuticals for cancer treatment, reported the closing of a $70 million Series C financing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The financing included strong participation from existing investors Duquesne Family Office and Bristol Myers Squibb, along with new investors Catalio Capital Management, Eli Lilly and Company, and Wasatch Group.
Proceeds from the financing will fuel Ratio’s next phase of growth. The company expects to use the funding to advance its ongoing ATLAS study evaluating its lead radiotherapeutic asset [Ac-225]RTX-2358 in advanced sarcomas, and to move its next-generation RLT candidate into the clinic. Ratio also plans to expand its discovery pipeline into new, high-value oncology targets, extending its radiopharmaceutical platform beyond its current indications and into additional tumor types with significant unmet need and substantial market potential. In parallel, the company will continue to strengthen its proprietary radiopharmaceutical technology and scale its manufacturing capabilities to support pipeline expansion and future commercial demand.
"This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead," said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. "As we march the ATLAS trial forward and prepare for our 5th IND filing, these proceeds are instrumental across the development and ultimately the supply of our targeted and PK-optimized radiopharmaceuticals."
"Ratio is a leader in radiopharmaceutical innovation and it has backed up science with execution — hitting clinical milestones, deepening strategic partnerships, and building the manufacturing infrastructure this modality demands," said Sue Meng, Managing Director of Duquesne Family Office. "We’ve tracked that progress closely, and our investment reflects our strong conviction in Ratio’s platform and its potential to change outcomes for patients."
(Press release, Ratio Therapeutics, JUL 31, 2026, View Source [SID1234669579])